<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04524689</url>
  </required_header>
  <id_info>
    <org_study_id>ACT16146</org_study_id>
    <secondary_id>U1111-1233-9798</secondary_id>
    <nct_id>NCT04524689</nct_id>
  </id_info>
  <brief_title>Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05)</brief_title>
  <acronym>CARMEN-LC05</acronym>
  <official_title>Open-label, Phase 2 Study of Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      â€¢To assess the tolerability and to determine the recommended doses of tusamitamab ravtansine&#xD;
      in combination with pembrolizumab and tusamitamab ravtansine in combination with&#xD;
      pembrolizumab and platinum-based chemotherapy with or without pemetrexed in the NSQ NSCLC&#xD;
      population&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To assess the safety and tolerability of tusamitamab ravtansine in combination with&#xD;
           pembrolizumab and tusamitamab ravtansine in combination with pembrolizumab and&#xD;
           platinum-based chemotherapy with or without pemetrexed&#xD;
&#xD;
        -  To assess the antitumor activity of tusamitamab ravtansine in combination with&#xD;
           pembrolizumab and tusamitamab ravtansine in combination with pembrolizumab, and&#xD;
           platinum-based chemotherapy, with or without pemetrexed in the NSQ NSCLC population&#xD;
&#xD;
        -  To assess the pharmacokinetics (PK) of tusamitamab ravtansine, pembrolizumab,&#xD;
           pemetrexed, cisplatin, and carboplatin, each when given in combination as a doublet&#xD;
           (tusamitamab ravtansine + pembrolizumab) or triplet (tusamitamab ravtansine +&#xD;
           pembrolizumab + platinum-based chemotherapy) or a quadruplet (tusamitamab ravtansine +&#xD;
           pembrolizumab + platinum-based chemotherapy + pemetrexed)&#xD;
&#xD;
        -  To assess the immunogenicity of tusamitamab ravtansine in combination with pembrolizumab&#xD;
           and tusamitamab ravtansine in combination with pembrolizumab and platinum-based&#xD;
           chemotherapy with or without pemetrexed&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The expected duration of the study intervention for participants may vary based on&#xD;
      progression date; median expected duration of study per participant is estimated 10 months&#xD;
      (up to 1 month for screening, a median of 6 months for treatment, and a median of 3 months&#xD;
      for end-of-treatment assessments and safety follow-up visit).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2020</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug-related dose-limiting toxicity (DLTs)</measure>
    <time_frame>Baseline up to 10 months after last participant treated</time_frame>
    <description>Study drug-related dose-limiting toxicity (DLTs) at Cycle 1 (C1D1 to C1D21), including but not limited to corneal toxicity. Each cycle is 21 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and laboratory abnormalities</measure>
    <time_frame>Baseline up to 10 months after last participant treated</time_frame>
    <description>TEAEs, SAEs and laboratory abnormalities according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) V5 -</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) of tusamitamab ravtansine + pembrolizumab + platinum based chemotherapy, with or without pemetrexed</measure>
    <time_frame>Baseline up to 10 months after last participant treated</time_frame>
    <description>ORR is defined as proportion of participants who have a confirmed complete response (CR) or partial response (PR) as per response evaluation criteria in solid tumors (RECIST v1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-therapeutic antibodies (ATAs) against tusamitamab ravtansine</measure>
    <time_frame>At cycle 1, 2, 3, 4,6, 8 then every 5 cycles and end of treatment. Each cycle is 21 days.</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)</condition>
  <arm_group>
    <arm_group_label>Tusamitamab ravtasine + Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab dose will be administered intravenously prior to intravenous administration of tusamitamab ravtansine dose every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tusamitamab ravtansine + Pembrolizumab + carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Carboplatin will be infused over 15 to 60 minutes immediately after tusamitamab ravtansine infusion on Day 1 and Q3W for the first 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tusamitamab ravtansine + Pembrolizumab + cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Cisplatin will be infused approximately 30 minutes after tusamitamab ravtansine infusion on Day 1 and Q3W for the first 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tusamitamab ravtansine + Pembrolizumab + carboplatin + pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Pemetrexed will be infused over 10 minutes after tusamitamab ravtansine infusion on Day 1 and then Q3W. Carboplatin will be infused over 15 to 60 minutes immediately after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tusamitamab ravtansine + Pembrolizumab + cisplatin + pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Pemetrexed will be infused over 10 minutes after tusamitamab ravtansine infusion on Day 1 and then Q3W. Cisplatin will be infused approximately 30 minutes after pemetrexed infusion after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR408701 (Tusamitamab ravtansine)</intervention_name>
    <description>Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous</description>
    <arm_group_label>Tusamitamab ravtansine + Pembrolizumab + carboplatin</arm_group_label>
    <arm_group_label>Tusamitamab ravtansine + Pembrolizumab + carboplatin + pemetrexed</arm_group_label>
    <arm_group_label>Tusamitamab ravtansine + Pembrolizumab + cisplatin</arm_group_label>
    <arm_group_label>Tusamitamab ravtansine + Pembrolizumab + cisplatin + pemetrexed</arm_group_label>
    <arm_group_label>Tusamitamab ravtasine + Pembrolizumab</arm_group_label>
    <other_name>Tusamitamab ravtansine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous</description>
    <arm_group_label>Tusamitamab ravtansine + Pembrolizumab + carboplatin</arm_group_label>
    <arm_group_label>Tusamitamab ravtansine + Pembrolizumab + carboplatin + pemetrexed</arm_group_label>
    <arm_group_label>Tusamitamab ravtansine + Pembrolizumab + cisplatin</arm_group_label>
    <arm_group_label>Tusamitamab ravtasine + Pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Pharmaceutical form: Lyophilized powder for reconstitution in solution Route of administration: Intravenous</description>
    <arm_group_label>Tusamitamab ravtansine + Pembrolizumab + cisplatin</arm_group_label>
    <arm_group_label>Tusamitamab ravtansine + Pembrolizumab + cisplatin + pemetrexed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous</description>
    <arm_group_label>Tusamitamab ravtansine + Pembrolizumab + carboplatin</arm_group_label>
    <arm_group_label>Tusamitamab ravtansine + Pembrolizumab + carboplatin + pemetrexed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous</description>
    <arm_group_label>Tusamitamab ravtansine + Pembrolizumab + carboplatin + pemetrexed</arm_group_label>
    <arm_group_label>Tusamitamab ravtansine + Pembrolizumab + cisplatin + pemetrexed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Histologically- or cytologically-confirmed diagnosis of advanced or metastatic NSQ&#xD;
             NSCLC with no EGFR sensitizing mutation or BRAF mutation or ALK/ROS alterations.&#xD;
&#xD;
          -  No prior systemic chemotherapy for the treatment of the participant's advanced or&#xD;
             metastatic disease (treatment with chemotherapy and/or radiation as part of&#xD;
             neoadjuvant/adjuvant therapy is allowed as long as completed at least 6 months prior&#xD;
             to diagnosis of advanced or metastatic disease).&#xD;
&#xD;
          -  Expression of CEACAM5 as demonstrated prospectively by a centrally assessed&#xD;
             Immunohistochemistry (IHC) assay of â‰¥2+ in intensity involving at least 50% (for Part&#xD;
             A and Part B) and at least 1% (for Part C) of the tumor cell population in archival&#xD;
             tumor sample (or if not available fresh biopsy sample).&#xD;
&#xD;
          -  Measurable disease based on RECIST 1.1.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
          -  Contraceptive use by men or women should be consistent with local regulations&#xD;
             regarding the methods of contraception for those participating in clinical studies&#xD;
&#xD;
          -  Capable of giving signed informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Medical condition requiring concomitant administration of a medication with a narrow&#xD;
             therapeutic window and metabolized by CYP450 or a strong CTP3A inhibitor.&#xD;
&#xD;
          -  Uncontrolled brain metastases and history of leptomeningeal disease.&#xD;
&#xD;
          -  Significant concomitant illness, including any severe medical condition that, in the&#xD;
             opinion of the investigator or Sponsor, would impair the patient's participation in&#xD;
             the study or interpretation of the results.&#xD;
&#xD;
          -  History within the last 3 years of an invasive malignancy other than the one treated&#xD;
             in this study, with the exception of resected/ablated basal or squamous-cell carcinoma&#xD;
             of the skin or carcinoma in situ of the cervix, or other local tumors considered cured&#xD;
             by local treatment.&#xD;
&#xD;
          -  History of known acquired immunodeficiency syndrome (AIDS) related illnesses or known&#xD;
             HIV disease requiring antiretroviral treatment, or active hepatitis A, B, or C&#xD;
             infection.&#xD;
&#xD;
          -  History of active autoimmune disease that has required systemic treatment in the past&#xD;
             2 years.&#xD;
&#xD;
          -  History of allogeneic tissue/solid organ transplantation.&#xD;
&#xD;
          -  Active infection requiring IV systemic therapy within 2 weeks prior to randomization&#xD;
             or active tuberculosis.&#xD;
&#xD;
          -  Interstitial lung disease or history of pneumonitis that has required oral or IV&#xD;
             steroids&#xD;
&#xD;
          -  Non-resolution of any prior treatment-related toxicity to &lt; Grade 2 according to NCI&#xD;
             CTCAE V5.0, with the exception of alopecia, vitiligo, or active thyroiditis controlled&#xD;
             with hormone replacement therapy.&#xD;
&#xD;
          -  Unresolved corneal disorder or any previous corneal disorder considered by an&#xD;
             ophthalmologist to predict higher risk of drug-induced keratopathy. The use of contact&#xD;
             lenses is not permitted.&#xD;
&#xD;
          -  Symptomatic herpes zoster within 3 months prior to screening.&#xD;
&#xD;
          -  Significant allergies to humanized monoclonal antibodies.&#xD;
&#xD;
          -  Clinically significant multiple or severe drug allergies, intolerance to topical&#xD;
             corticosteroids, or severe post-treatment hypersensitivity reactions (including, but&#xD;
             not limited to, erythema multiforme major, linear immunoglobulin A [IgA] dermatosis,&#xD;
             toxic epidermal necrolysis, and exfoliative dermatitis).&#xD;
&#xD;
          -  Concurrent treatment with any other anticancer therapy.&#xD;
&#xD;
          -  Have received prior chemotherapy treatment for advanced/metastatic NSCLC.&#xD;
&#xD;
          -  The patient is a candidate for a curative treatment with either surgical resection&#xD;
             and/or chemoradiation&#xD;
&#xD;
          -  Washout period before the first administration of study intervention of less than 3&#xD;
             weeks or less than 5 times the half-life, whichever is shorter, for any&#xD;
             investigational treatment).&#xD;
&#xD;
          -  Any prior therapy targeting CEACAM5.&#xD;
&#xD;
          -  Any prior treatment with any other anti-PD-1, or PD-L1 or programmed death ligand 2&#xD;
             (PD-L2), anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4.&#xD;
&#xD;
          -  Any prior maytansinoid treatment (DM1 or DM4 ADC).&#xD;
&#xD;
          -  Is receiving systemic steroid therapy â‰¤3 days prior to the first dose of study therapy&#xD;
             or receiving any other form of immunosuppressive medication. Daily steroid replacement&#xD;
             therapy or any corticosteroid premedication if applicable are allowed.&#xD;
&#xD;
          -  Any radiation therapy to lung &gt;30 Gy within 6 months of first study intervention&#xD;
             administration.&#xD;
&#xD;
          -  Has received or will receive a live vaccine within 30 days prior to the first study&#xD;
             intervention administration.&#xD;
&#xD;
          -  Any major surgery within the preceding 3 weeks of the first study intervention&#xD;
             administration.&#xD;
&#xD;
        Prior/concurrent clinical study experience&#xD;
&#xD;
          -  Current participation in any other clinical study involving an investigational study&#xD;
             treatment or any other type of medical research.&#xD;
&#xD;
          -  Poor organ function&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number :8400002</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400004</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400001</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0360003</name>
      <address>
        <city>Macquarie Park</city>
        <state>New South Wales</state>
        <zip>2109</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0360001</name>
      <address>
        <city>Heidelberg West</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1520002</name>
      <address>
        <city>Santiago</city>
        <state>Reg Metropolitana De Santiago</state>
        <zip>7500713</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1520001</name>
      <address>
        <city>Santiago</city>
        <state>Reg Metropolitana De Santiago</state>
        <zip>8420383</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1520003</name>
      <address>
        <city>ViÃ±a del Mar</city>
        <state>ValparaÃ­so</state>
        <zip>2520598</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2030001</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2030002</name>
      <address>
        <city>Ostrava - Vitkovice</city>
        <zip>70384</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2500005</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2500003</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2500001</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2500004</name>
      <address>
        <city>Poitiers Cedex</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3480002</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3480003</name>
      <address>
        <city>Budatest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3480004</name>
      <address>
        <city>FarkasgyepÃ¼</city>
        <zip>8582</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3480006</name>
      <address>
        <city>KecskemÃ©t</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3760004</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3760001</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3760002</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240005</name>
      <address>
        <city>La CoruÃ±a</city>
        <state>A CoruÃ±a [La CoruÃ±a]</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240003</name>
      <address>
        <city>Valencia / Valencia</city>
        <state>Valenciana, Comunidad</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240002</name>
      <address>
        <city>Las Palmas</city>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240004</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240001</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Chile</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 29, 2021</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2020</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Maytansine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

